Placental transfer of sulindac and its active sulfide metabolite in humans
WB Kramer, G Saade, CN Ou, R Cheryl, D Karen… - American journal of …, 1995 - Elsevier
OJECTIVE: Our aim was to investigate whether the human placenta is permeableto sulindc
or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational
age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to
6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each
procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were
measured by high-performance liquid chromatography. RESULTS: The maternal sulfide …
or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational
age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4. to
6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each
procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were
measured by high-performance liquid chromatography. RESULTS: The maternal sulfide …